JPWO2021100027A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021100027A5
JPWO2021100027A5 JP2022529348A JP2022529348A JPWO2021100027A5 JP WO2021100027 A5 JPWO2021100027 A5 JP WO2021100027A5 JP 2022529348 A JP2022529348 A JP 2022529348A JP 2022529348 A JP2022529348 A JP 2022529348A JP WO2021100027 A5 JPWO2021100027 A5 JP WO2021100027A5
Authority
JP
Japan
Prior art keywords
wound
around
compound
wounds
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022529348A
Other languages
Japanese (ja)
Other versions
JP2023503886A (en
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/061043 external-priority patent/WO2021100027A1/en
Publication of JP2023503886A publication Critical patent/JP2023503886A/en
Publication of JPWO2021100027A5 publication Critical patent/JPWO2021100027A5/ja
Pending legal-status Critical Current

Links

Claims (29)

式Ｉの化合物
Figure 2021100027000001
［式中、Ｘ－は任意のハロゲンである。］
を含む、それを必要とする対象において、創傷、創傷の治癒不良、創傷およびその周辺の脱毛、創傷およびその周辺の瘢痕および／またはしわ、乾癬、またはそれらの任意の組み合わせを治療する方法のための医薬組成物であって、前記方法が、治療有効量の式Ｉの化合物を、前記対象の患部に局所的に投与することを含む、前記医薬組成物。 Compounds of formula I
Figure 2021100027000001
[In the formula, X − is any halogen. ]
For a method of treating a wound, poor healing of a wound, hair loss in and around a wound, scarring and/or wrinkles in and around a wound, psoriasis, or any combination thereof, in a subject in need thereof, including: A pharmaceutical composition, wherein the method comprises administering a therapeutically effective amount of a compound of Formula I locally to the affected area of the subject. 前記創傷が、糖尿病性創傷、切開創、外科的創傷、偶発的創傷、圧迫潰瘍／褥瘡、糖尿病性足部潰瘍、壊疽性膿皮症、熱傷、病変、または切り傷から選択される、請求項１に記載の医薬組成物。 2. The wound is selected from diabetic wounds, incisions, surgical wounds, accidental wounds, pressure ulcers/bedsores, diabetic foot ulcers, pyoderma gangrenosum, burns, lesions, or cuts. The pharmaceutical composition described in . 前記方法が創傷を治療する、請求項１または請求項２に記載の医薬組成物。 3. A pharmaceutical composition according to claim 1 or claim 2, wherein the method treats a wound. 前記方法が、創傷の治癒不良を治療する、請求項１または請求項２に記載の医薬組成物。 3. The pharmaceutical composition of claim 1 or claim 2, wherein the method treats poor wound healing. 前記方法が創傷およびその周辺の脱毛を治療する、請求項１または請求項２に記載の医薬組成物。 3. A pharmaceutical composition according to claim 1 or claim 2, wherein the method treats hair loss in and around a wound. 前記方法が、創傷およびその周辺の瘢痕および／またはしわを治療する、請求項１または請求項２に記載の医薬組成物。 3. A pharmaceutical composition according to claim 1 or claim 2, wherein the method treats scars and/or wrinkles in and around the wound. 前記方法が乾癬を治療する、請求項１または請求項２に記載の医薬組成物。 3. A pharmaceutical composition according to claim 1 or claim 2, wherein the method treats psoriasis. 前記治療が、前記創傷部位およびその周辺の前記瘢痕および／またはしわの外観を低減、最小化、または消失させることによって特徴付けられる、請求項６に記載の医薬組成物。 7. Pharmaceutical composition according to claim 6, wherein said treatment is characterized by reducing, minimizing or eliminating the appearance of said scars and/or wrinkles at and around said wound site. 前記治療が、前記創傷部位およびその周辺の発毛を増進および／または促進することによって特徴付けられる、請求項５に記載の医薬組成物。 Pharmaceutical composition according to claim 5, wherein the treatment is characterized by increasing and/or promoting hair growth at and around the wound site. ＸがＢｒ－またはＣｌ－である、請求項１～９のいずれか一項に記載の医薬組成物。 Pharmaceutical composition according to any one of claims 1 to 9, wherein X is Br - or Cl - . 式Ｉの前記化合物が、
Figure 2021100027000002
である、請求項１～９のいずれか一項に記載の医薬組成物。 Said compound of formula I is
Figure 2021100027000002
The pharmaceutical composition according to any one of claims 1 to 9, which is 創傷、創傷の治癒不良、創傷およびその周辺の脱毛、創傷およびその周辺の瘢痕および／またはしわ、および乾癬から成る群から選択される一つ以上の状態の治療において、それを必要とする対象の患部に局所投与することによって使用するための式Ｉの化合物であり、
Figure 2021100027000003
式中、Ｘ－は任意のハロゲンである、化合物。 in a subject in need thereof in the treatment of one or more conditions selected from the group consisting of wounds, poor healing of wounds, hair loss in and around wounds, scarring and/or wrinkles in and around wounds, and psoriasis. A compound of formula I for use by topical administration to the affected area,
Figure 2021100027000003
A compound in which X - is any halogen. 前記創傷が、糖尿病性創傷、切開創、外科的創傷、偶発的創傷、圧迫潰瘍／褥瘡、糖尿病性足部潰瘍、壊疽性膿皮症、熱傷、病変、および切り傷から選択される、請求項１２に記載の化合物。 12. The wound is selected from diabetic wounds, incisions, surgical wounds, accidental wounds, pressure ulcers/bedsores, diabetic foot ulcers, pyoderma gangrenosum, burns, lesions, and cuts. Compounds described in. 前記状態が創傷である、請求項１２または１３に記載の化合物。 14. A compound according to claim 12 or 13, wherein the condition is a wound. 前記状態が、創傷の治癒不良である、請求項１２または１３に記載の化合物。 14. A compound according to claim 12 or 13, wherein the condition is poor wound healing. 前記状態が、創傷およびその周辺の脱毛である、請求項１２または１３に記載の化合物。 14. A compound according to claim 12 or 13, wherein the condition is hair loss in and around a wound. 前記状態が、創傷およびその周辺の瘢痕および／またはしわである、請求項１２または１３に記載の化合物。 14. A compound according to claim 12 or 13, wherein the condition is scarring and/or wrinkles in and around a wound. 前記状態が乾癬である、請求項１２または１３に記載の化合物。 14. A compound according to claim 12 or 13, wherein said condition is psoriasis. 前記治療が、前記創傷部位およびその周辺の前記瘢痕および／またはしわの外観を低減、最小化、または消失させることによって特徴付けられる、請求項１２または請求項１３に記載の化合物。 14. A compound according to claim 12 or claim 13, wherein the treatment is characterized by reducing, minimizing or eliminating the appearance of the scar and/or wrinkles at and around the wound site. 前記治療が、前記創傷部位およびその周辺の発毛を増進および／または促進することによって特徴付けられる、請求項１２または請求項１３に記載の化合物。 14. A compound according to claim 12 or claim 13, wherein the treatment is characterized by increasing and/or promoting hair growth at and around the wound site. ＸがＢｒ－またはＣｌ－である、請求項１２～２０のいずれか一項に記載の化合物。 A compound according to any one of claims 12 to 20, wherein X is Br - or Cl - . 式Ｉの前記化合物が、化合物１である、請求項１２～２０のいずれか一項に記載の化合物。
Figure 2021100027000004
A compound according to any one of claims 12 to 20, wherein the compound of formula I is compound 1.
Figure 2021100027000004
 創傷の治療、創傷の治癒不良、創傷およびその周辺の脱毛、創傷およびその周辺の瘢痕および／またはしわ、乾癬、またはそれらの任意の組み合わせ、および薬学的に許容可能な賦形剤の治療に使用するための局所用組成物であって、前記組成物が、式Ｉの化合物、
Figure 2021100027000005
［式中、Ｘ－は、任意のハロゲンである。］および薬学的に許容可能な賦形剤を含む、局所用組成物。 Used in the treatment of wounds, poor healing of wounds, hair loss in and around the wound, scarring and/or wrinkles in and around the wound, psoriasis, or any combination thereof, and pharmaceutically acceptable excipients. A topical composition for treating a compound of formula I, said composition comprising:
Figure 2021100027000005
[In the formula, X − is any halogen. ] and a pharmaceutically acceptable excipient. Ｘ－がＢｒ－またはＣｌ－である、請求項２３に記載の局所用組成物。 24. The topical composition of claim 23, wherein X- is Br- or Cl- . Ｘ－がＢｒ－である、請求項２３に記載の局所用組成物。 24. The topical composition of claim 23, wherein X- is Br-. 前記薬学的に許容可能な賦形剤が、乳化剤、防腐剤、またはそれらの任意の組み合わせのうちの一つ以上である、請求項２３に記載の局所用組成物。 24. The topical composition of claim 23, wherein the pharmaceutically acceptable excipient is one or more of an emulsifier, a preservative, or any combination thereof. 創傷、創傷の治癒不良、創傷およびその周辺の脱毛、創傷およびその周辺の瘢痕および／またはしわ、乾癬、またはそれらの任意の組み合わせを治療するためのキットであって、式Ｉの化合物を含み、
Figure 2021100027000006
［式中、Ｘ－は任意のハロゲンである。］
任意で、キットを使用するための使用説明書を含む、キット。 A kit for treating a wound, poor wound healing, hair loss in and around a wound, scarring and/or wrinkles in and around a wound, psoriasis, or any combination thereof, comprising a compound of formula I;
Figure 2021100027000006
[In the formula, X − is any halogen. ]
A kit, optionally including instructions for using the kit. Ｘ－がＢｒ－またはＣｌ－である、請求項２７に記載のキット。 28. The kit according to claim 27, wherein X- is Br- or Cl- . Ｘ－がＢｒ－である、請求項２７に記載のキット。 28. The kit of claim 27, wherein X- is Br- .
JP2022529348A 2019-11-22 2020-11-23 Anti-inflammatory compounds for the treatment of skin disorders Pending JP2023503886A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201911047906 2019-11-22
IN201911047906 2019-11-22
PCT/IB2020/061043 WO2021100027A1 (en) 2019-11-22 2020-11-23 Anti-inflammatory compounds for use in the treatment of dermal disorders

Publications (2)

Publication Number Publication Date
JP2023503886A JP2023503886A (en) 2023-02-01
JPWO2021100027A5 true JPWO2021100027A5 (en) 2023-10-31

Family

ID=73654855

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022529348A Pending JP2023503886A (en) 2019-11-22 2020-11-23 Anti-inflammatory compounds for the treatment of skin disorders

Country Status (9)

Country Link
US (1) US20220296618A1 (en)
EP (1) EP4061355A1 (en)
JP (1) JP2023503886A (en)
CN (1) CN114727982B (en)
AR (1) AR127082A1 (en)
AU (1) AU2020386863A1 (en)
CA (1) CA3158840A1 (en)
TW (1) TW202123932A (en)
WO (1) WO2021100027A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022287326A1 (en) * 2021-06-04 2023-11-30 Council Of Scientific & Industrial Research siRNA DELIVERY VECTOR

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270999B (en) * 1994-07-26 1997-05-26 Indena Spa FORMULATIONS BASED ON CUMARINES AND THEIR USE IN THE PHARMACEUTICAL AND COSMETIC FIELD
GB2540234B (en) * 2015-02-19 2020-12-02 Council Scient Ind Res An antioxidant compound having anti atherosclerotic effect and preparation thereof

Similar Documents

Publication Publication Date Title
JPWO2006109734A1 (en) External preparation for wound treatment
US11850219B2 (en) Inositol-stabilized arginine-silicate for hair growth and thickening
AU2004290463A1 (en) Method and composition for treatment of cutaneous lesions
Meaume et al. Urgotul®: a novel non-adherent lipidocolloid dressing
Carneiro et al. Topical phenytoin versus EUSOL in the treatment of non-malignant chronic leg ulcers
US20210236446A1 (en) Wound healing composition
JPWO2021100027A5 (en)
US11654155B2 (en) Therapeutic material for skin ulcer
US6958159B2 (en) Pharmaceutical gel composition
Fosko et al. Nasal reconstruction with the cheek island pedicle flap
JP2640597B2 (en) Wound healing promoter
CN114727982B (en) Anti-inflammatory compounds for use in the treatment of skin disorders
JP5734953B2 (en) Pharmaceutical composition for the treatment or prevention of burn injury
JP2013513579A (en) Pharmaceutical composition for treating skin burns
US10905729B1 (en) Formulations and methods for wound treatment
RU2761411C1 (en) Method for surgical treatment of ingrown nail
Falanga et al. Zinc chloride paste for the debridement of chronic leg ulcers
WO2018145147A1 (en) A method of treating a fibrotic condition associated with excessive collagen formation using activators of the collagenase production pathway.
WO2019150173A1 (en) Tibo (topical innovative burn ointment)
JP2004262772A (en) Glycyrrhizin-containing percutaneous pharmaceutical preparation
WO2022218136A1 (en) Use of adenine in preparation of drug for treating diabetic ulcers
AU2001242100B2 (en) Pharmaceutical gel composition
RU2579429C2 (en) Method for surgical treatment of ingrown nail of first toe
Nainpuriya et al. Trends in keloids an hypertrophic scars
RU2021130022A (en) APPLICATION OF EPIDERMAL GROWTH FACTOR IN THE TREATMENT OF DIABETIC FOOT ULCER